Where can I buy F-star Therapeutics stock?
Shares of FSTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is F-star Therapeutics' stock price today?
What is AFF-star Therapeutics?
F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies.
Where can I buy shares of fstx?
Shares of FSTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is F-Star Therapeutics a buy?
F-star Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.
Is FSTX stock a good buy?
The 4 analysts offering 12-month price forecasts for F-Star Therapeutics Inc have a median target of 11.00, with a high estimate of 32.00 and a low estimate of 7.00. The median estimate represents a +78.86% increase from the last price of 6.15.
What does F-Star therapeutics do?
Corporate Profile. F-star is a clinical-stage immuno-oncology company focused on transforming the lives of patients with cancer through the development of F-star's innovative tetravalent mAb2 bispecific antibodies.
Are bispecific antibodies monoclonal?
Bispecific antibodies are artificial proteins that have promising applications in the field of cancer immunotherapy. They are comprised of two monoclonal antibodies held together by a flexible peptide linker. As the name suggests, this makes them able to bind to two different antigens.
Should I buy or sell F-star Therapeutics stock right now?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for F-star Therapeutics in the last twelve months. There are...
What is F-star Therapeutics' stock price forecast for 2022?
5 analysts have issued 12-month price objectives for F-star Therapeutics' shares. Their forecasts range from $15.00 to $35.00. On average, they exp...
How has F-star Therapeutics' stock price performed in 2022?
F-star Therapeutics' stock was trading at $5.02 on January 1st, 2022. Since then, FSTX shares have decreased by 28.7% and is now trading at $3.58....
Are investors shorting F-star Therapeutics?
F-star Therapeutics saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 316,800 shares, an...
When is F-star Therapeutics' next earnings date?
F-star Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for...
How were F-star Therapeutics' earnings last quarter?
F-star Therapeutics, Inc. (NASDAQ:FSTX) issued its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.57) earnings per shar...
Who are F-star Therapeutics' key executives?
F-star Therapeutics' management team includes the following people: Dr. Eliot Richard Forster M.B.A. , Ph.D., Pres, CEO & Director (Age 56, Pay...
Who are some of F-star Therapeutics' key competitors?
Some companies that are related to F-star Therapeutics include Fulcrum Therapeutics (FULC) , Generation Bio (GBIO) , Affimed (AFMD) , Vaxxinity...
What is F-star Therapeutics' stock symbol?
F-star Therapeutics trades on the NASDAQ under the ticker symbol "FSTX."
About F-star Therapeutics
F-star Therapeutics (NASDAQ:FSTX) Frequently Asked Questions
F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies.
What is F star?
7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for F-star Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock.
Does market cap include convertible securities?
F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.
